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NF-kB comprises a family of transcription factors that regulate key immune processes. In this study, the effects of
orthopoxvirus infection upon the activation of NF-kB were examined. During the early phase of infection, cowpox virus can
inhibit the induction of NF-kB-regulated gene expression by interfering with the process of IkBa degradation. Although either
okadaic acid or tumor necrosis factor (TNF) treatment of infected cells can induce IkBa phosphorylation, further processing
of IkBa is inhibited. These results suggest that cowpox virus is capable of inhibiting the activation of NF-kB at a point where
multiple signal transduction pathways converge. Other orthopoxviruses affect NF-kB activity, but in a type-specific manner.
Raccoonpox virus and vaccinia virus (Copenhagen strain) negatively affect NF-kB induction by TNF. In contrast, the modified
vaccinia virus Ankara strain induces NF-kB activation, even in the absence of other stimuli. These findings suggest that
orthopoxviruses may affect a broad range of virus–host interactions through their effects upon NF-kB activation. Moreover,
because of the central role for NF-kB in immune processes and disease, these type-specific effects may contribute
significantly to the immunogenic and pathogenic properties of poxviruses. © 2001 Academic Press
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INTRODUCTION
NF-kB comprises a family of transcription factors that
regulate the expression of numerous genes encoding
proteins that are crucial elements of innate and acquired
immune responses. In particular, NF-kB increases the
xpression of many genes, such as those encoding MHC
lass I, the TAP1 peptide transporter, adhesion mole-
ules, cellular inhibitor of apoptosis proteins (c-IAPs),
nterferon, tumor necrosis factor (TNF), and other pro-
nflammatory cytokines, which are important in response
o viral infection (reviewed by Baldwin, 1996; Blackwell
nd Christman, 1997; Ghosh et al., 1998; Foo and Nolan,
999). NF-kB also regulates the expression of genes
involved in the control of cell proliferation and apoptosis
(reviewed by Chen et al., 1999; Baldwin, 2001a,b).
The potency and the broad range of effects of NF-kB-
regulated gene expression dictate that the activation of
NF-kB transcription factors must be stringently con-
trolled. Current information on the signaling pathways
leading to the activation of NF-kB has recently been
reviewed by Karin and Ben-Neriah (2000). The primary
mechanisms of control can be summarized as follows. In
unstimulated cells, the majority of NF-kB is held in the
ytoplasm by members of the IkB family of inhibitor
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Microbiology, Box 3020, Duke University
edical Center, Durham, NC 27710. Fax: (919) 684-8735. E-mail:
icku001@mc.duke.edu.
175mmunity; modified vaccinia Ankara.
proteins; for example, IkBa can control the activation of
50/p65 heterodimer NF-kB. In stimulated cells, NF-kB
translocates to the nucleus as a result of the IkBa being
degraded. This degradation can be initiated by a variety
of stimuli, including cytokines such as TNF, interleu-
kin-1b (IL-1b), and interleukin-18 (IL-18); lipopolysaccha-
ride; phosphatase inhibitors such as okadaic acid; and
the activation of the dsRNA-dependent protein kinase
(PKR). Each of these factors can induce the activation of
kinases, notably the IkB kinase (IKK) complex, which
ultimately phosphorylates two serines (ser 32 and ser 36)
near the amino terminus of IkBa. The phosphorylated
IkBa is recognized as a substrate for ubiquitination,
which targets it for degradation by the 26S proteasome.
Once released from IkBa, NF-kB translocates to the
ucleus where it can function as a transcriptional acti-
ator.
The potency and broad range of effects of NF-kB-
regulated gene expression also suggest that either viral
inhibition, or alternatively, viral induction, of NF-kB activ-
ity will markedly affect the interactions between the virus
and the host. The nature of these interactions is likely to
have important consequences for viral replication, the
pathogenic effects of virus infection, and the immuno-
genic effects of live virus vaccines.
Viruses of several families actively inhibit immune
responses (reviewed by Spriggs, 1996; Tortorella et al.,
2000), but among these, the poxviruses are especially
adept at interfering with immune processes (reviewed by
Smith, 1999; Alcami and Koszinowski, 2000; Barrett et al.,
0042-6822/01 $35.00
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ND PIC2001; Moss and Shisler, 2001). There are two major
contributory factors for this. First, poxvirus genomes typ-
ically encode 150–200 proteins. As a result, poxviruses
have greater capacities than many other viruses to en-
code proteins that interfere with host immune responses.
Second, in comparison to other DNA viruses, the poxvi-
ruses are unusually independent of the host transcrip-
tional machinery, because they encode most of the en-
zymes and factors needed to effect viral transcription.
This property contributes to the abilities of the poxvi-
ruses to interfere with the expression of host genes
without adversely affecting the expression of viral genes.
For these reasons the poxviruses are especially well-
suited to affect the activation of NF-kB.
Poxviruses are likely to benefit the most from specific
mechanisms for affecting NF-kB function either in in-
fected cells during the early phase of virus replication or
in uninfected cells prior to their infection. In general
during these phases, host-cell gene expression appears
to be fully functional, suggesting that such cells should
retain their responsiveness to NF-kB-activating stimuli,
as well as the potential to effect NF-kB-regulated gene
xpression.
Many poxviruses are already known to encode pro-
eins that could affect the activation of NF-kB. For
example, several poxviruses produce soluble, se-
creted versions of receptors for the cytokines TNF,
lymphotoxin-a, IL-1b, IL-18, and CD153, each of which
can activate NF-kB (Smith et al., 1990, 1991, 1996; Hu et
al., 1994; Loparev et al., 1998; Saraiva and Alcami,
001; unpublished data). Also, some poxviruses en-
ode caspase inhibitors, such as CrmA, which can
nhibit caspase-1-mediated processing of pro-IL-1b
and pro-IL-18 to the mature, active forms (Ray et al.,
1992). There are poxvirus inhibitors of PKR, which
might interfere with PKR-dependent activation of
NF-kB (Chang et al., 1992; Davies et al., 1992; Kumar et
al., 1994). Additionally, it was recently reported that
vaccinia virus encodes two proteins that share amino
acid similarity with the Toll/IL-1 receptor (TIR) domain
and that these are capable of antagonizing signal
transduction through IL-1 and Toll-like receptors
(Bowie et al., 2000). Conversely, many poxviruses,
such as various strains of vaccinia and variola viruses,
lack several of these potential inhibitors of NF-kB
activation (Goebel et al., 1990; Massung et al., 1993;
Shchelkunov et al., 1993; Antoine et al., 1998). Further-
more, many poxviruses encode proteins such as vac-
cinia growth factor, a protein similar to epidermal
growth factor, which is capable of the activation of
NF-kB (Blomquist et al., 1984; Brown et al., 1985;
Twardzik et al., 1985; Sun and Carpenter, 1998; Biswas
et al., 2000). Therefore, different poxviruses may have
the potential capacity to affect the activation of NF-kB
176 OIE An a variety of different ways.
Interference with the activation of NF-kB represents anxceptional strategy that a poxvirus could use to counter
ultiple immune processes through the targeting of a
ingle regulatory process. However, the currently char-
cterized poxvirus proteins that might interfere with
F-kB activation have the potential to affect only a few of
the many stimuli and signal transduction pathways that
can induce this transcription factor. Moreover, the pri-
mary functions of these viral proteins may be unrelated
to their potential effects upon NF-kB activation. Despite
the importance of NF-kB in immune processes, little is
nown about the effects of either particular poxvirus
roteins, or poxvirus replication in general, upon NF-kB
activation in virus-infected cells. Therefore, in this study
we have examined the effects of various poxviruses
upon NF-kB activation. Further, we have examined the
ypothesis that poxviruses may have the ability to inter-
ere comprehensively with the activation of NF-kB by
specifically targeting regulatory events that are common
to the multiple pathways leading to the activation of
NF-kB.
RESULTS
Cowpox virus can specifically inhibit NF-kB-regulated
ene expression
To determine whether cowpox virus interferes with
F-kB function, we examined the expression of authentic
and artificial NF-kB-regulated genes in virus-infected
ells.
First, an RNase protection assay was used to com-
are the effects of cowpox virus infection and TNF
reatment on the quantities of the mRNAs of 11 genes,
hree of which, traf1, c-iap-1, and c-iap-2, are known to
e regulated by NF-kB (Chu et al., 1997; Wang et al.,
998; Schwenzer et al., 1999). TNF stimulation of un-
nfected HeLa cells, over a 90-min period, resulted in
he increased accumulation of TRAF1, c-IAP-1, and
-IAP-2 mRNAs (Fig. 1, lanes 4–7). However, in the
irus-infected cells, there was no observable increase
n the quantities of these three mRNAs either as a
esult of the virus infection (Fig. 1, lane 8, in compar-
son to lane 4) or in response to TNF treatment (Fig. 1,
anes 9–11 in comparison to lanes 5–7). Neither cow-
ox virus infection nor TNF treatment affected the
ccumulation of the RNAs of the other genes, suggest-
ng that the virus may specifically affect the expression
f NF-kB-regulated genes.
Second, the effects of cowpox virus infection upon the
expression of the firefly luciferase gene under the control
of an NF-kB-regulated promoter were examined. For con-
trol purposes, the effects of virus infection upon the
expression of a cotransfected sea pansy luciferase gene,
under the control of a constitutively active promoter,
were also examined. Transfected HEK 293T cells in-
KUPfected with cowpox virus showed almost no change in
firefly luciferase activity in response to TNF treatment,
ITH Twhereas TNF treatment of uninfected cells resulted in a
9.2-fold relative increase in firefly luciferase activity over
that in untreated cells (Fig. 2).
Infection of the cotransfected cells with cowpox virus
did not induce expression of either luciferase gene. In-
stead, expression of the firefly and sea pansy luciferase
genes was about 40% lower in virus-infected cells than
uninfected cells (Fig. 2). This reduction almost certainly
reflects the progressive general inhibition of host mac-
romolecular synthesis that begins during the late phase
of virus replication. This effect is a factor in reporter
FIG. 1. In HeLa cells infected with cowpox virus, quantities of the
mRNAs of NF-kB-regulated genes traf1, c-iap-1, and c-iap-2 are not
increased either by virus infection or by TNF treatment. Four hours after
infection, uninfected HeLa cells (lanes 4–7) or cowpox virus-infected
HeLa cells (10 PFU/cell; lanes 8–11) were treated with TNF (20 ng/ml)
for the indicated periods of time. Total cellular RNAs were harvested
and analyzed by RNase protection assay using anti-sense RNA probes
generated from cDNA templates derived from the indicated genes.
Arrows indicate the positions of the protected fragments of TRAF1,
c-IAP-1, and c-IAP-2 RNAs. Lane 1 contains unbound probes; lanes 2
and 3 contain assay products resulting from probe hybridization to
negative-control yeast tRNAs and positive-control HeLa cell RNAs,
respectively. Abbreviations are as follows: XIAP, X chromosome-linked
inhibitor of apoptosis protein; TRAF, tumor necrosis factor receptor-
associated factor; NAIP, neuronal apoptosis inhibitory protein; c-IAP,
cellular inhibitor of apoptosis protein; TRPM2, testosterone-repressed
prostate message-2; L32, 50 S ribosomal protein L32; and GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
POXVIRUS INTERFERENCE Wassays of this type, because after TNF treatment, the
cells are normally incubated for 4 h to allow adequatetime for the synthesis of the reporter luciferase enzyme.
Consequently, even though the virus-infected cells may
be treated with TNF during the early phase of virus
replication, some of the subsequent expression of the
luciferase gene will occur after the late phase of viral
replication has begun.
These luciferase data are consistent with the results of
the RNase protection experiments, suggesting that cow-
pox virus infection per se does not induce NF-kB-regu-
lated gene expression, and further, that cowpox virus can
specifically inhibit inducible NF-kB-regulated gene ex-
pression.
FIG. 2. Cowpox virus (CPV) inhibits TNF-induced expression of a
luciferase gene under the control of an NF-kB-regulated promoter. HEK
293T cells were transiently cotransfected with two vectors: a control
vector designed to give constitutive expression of a sea pansy lucif-
erase gene, and an NF-kB reporter vector for the inducible expression
of a firefly luciferase gene. At 19 h post-transfection, the cells were
either mock-infected with human 143B cell lysate or infected with
cowpox virus (10 PFU/cell). Cells were either left untreated or treated
with TNF (20 ng/ml) from 4 to 8 h postinfection and then assayed for
both sea pansy and firefly luciferase activity. (Table) The average of
three independent transfections is represented by each luciferase
value. (Bar graph) The graph shows the relative change in firefly
luciferase activity compared with untreated, mock-infected cells. The
177HE REGULATION OF NF-kBfirefly luciferase values are standardized using the sea pansy lucif-
erase values from the constitutively active promoter.
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leading to NF-kB activation
Specific inhibition of NF-kB-regulated gene expres-
sion by cowpox virus might be predicted to involve early-
class gene products that target components of signal
transduction pathways leading to the activation of these
transcription factors. Therefore, we examined the effects
of cowpox virus infection upon NF-kB signaling path-
ways.
A key regulatory step in the activation of NF-kB-regu-
lated gene expression is the translocation of NF-kB from
the cytoplasm to the nucleus. Once in the nucleus, NF-kB
can bind to kB elements to contribute to the transcription
f specific genes. Electrophoretic mobility shift assays
howed that cowpox virus infection inhibits the accumu-
ation of nuclear NF-kB capable of binding to kB sites
(Fig. 3). Extracts from uninfected, TNF-treated cells pro-
duced a specific complex that was shown by supershift
analysis to contain the p50 and p65 subunits of NF-kB
(Fig. 3A). Formation of this specific complex was unaf-
fected by the addition of a 100-fold molar excess of
oligonucleotides lacking the consensus NF-kB binding
site sequence; yet when the extracts were incubated
with a 100-fold molar excess of the unlabeled probe,
complex formation was no longer detected, demonstrat-
ing the binding specificity of the p50/p65 complex for kB
lements (data not shown).
FIG. 3. Cowpox virus inhibits TNF-induced nuclear accumulation of
prepared both from uninfected HEK 293 cells and from cowpox virus-in
or without TNF treatment (5 ng/ml for 15 min). The nuclear extracts fro
consensus NF-kB binding-site sequence. Resultant complex formation w
nduces p50/p65 NF-kB complex formation in uninfected cells. For supe
were preincubated with goat antibodies against the p50 (lane 3) or p
Uninfected HEK 293 cells (lanes 1–2) or HEK 293 cells infected with co
cells were either untreated or treated with TNF for the 15 min prior to
178 OIE ACowpox virus infection resulted in the progressive
eduction of the amount of TNF-induced nuclear NF-kB t(p50/p65) capable of binding to the kB-site containing
ligonucleotides (Fig. 3B). This effect became evident at
h postinfection, with little or no complex formation
etectable after 4 h of infection. The timing of the viral
nhibition of complex formation suggested that viral early
ene functions are involved, because in this system, the
ate phase is not initiated until viral DNA replication
egins, at about 4 h after infection.
Evidence that viral late gene functions are not neces-
ary for this inhibition was provided by analysis of com-
lex formation in virus-infected cells cultured in the pres-
nce of cytosine-arabinoside (AraC), which prevents viral
NA replication, thereby inhibiting normal intermediate
nd late viral gene expression (Keck et al., 1990). Under
these conditions, nuclear extracts of virus-infected cells
still failed to accumulate p50/p65 capable of binding to
kB-site oligonucleotides (Fig. 4, lanes 5–8). In uninfected
cells, AraC treatment had no effect upon the accumula-
tion of p50/p65 capable of binding to kB-site oligonucle-
otides after TNF treatment (Fig. 4, lanes 1–4). In these
experiments, the efficacy of the AraC treatment in block-
ing cowpox virus DNA replication was confirmed by
hybridization analysis of DNA isolated from the cells,
using the PstI F fragment of the cowpox virus genome as
a probe (data not shown).
The viral inhibition of the accumulation of nuclear
NF-kB capable of binding to kB sites suggested that the
capable of binding to kB-site oligonucleotides. Nuclear extracts were
HEK 293 cells (5 PFU/cell) at various times after infection, either with
cells were incubated with radiolabeled oligonucleotides containing a
lyzed by electrophoretic mobility shift assay (EMSA). (A) TNF treatment
nalysis, prior to being incubated with the oligonucleotides, the extracts
e 4) subunits of human NF-kB or with normal goat serum (NGS). (B)
irus (lanes 3–12) were harvested at the indicated hours postinfection;
t.
KUPNF-kB
fected
m the
as ana
rshift a
65 (lan
ND PICvirus might interfere with the translocation of NF-kB from
he cytoplasm to the nucleus. Such translocation of p50/
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ITH Tp65 NF-kB is governed by the degradation of IkBa. Ac-
ordingly, we next examined the effects of cowpox virus
nfection upon IkBa degradation. Normally, IkBa is de-
raded within 15 min of TNF stimulation in TNF-respon-
ive cells. However, in either HEK 293 cells (Fig. 5) or
eLa cells (data not shown), cowpox virus infection re-
ulted in the inhibition of TNF-induced degradation of
kBa. In uninfected cells, IkBa in the cytoplasm was
replenished after 90 min of TNF treatment (Fig. 5A).
Presumably, this occurred because the synthesis of IkBa
is under the control of NF-kB and because mechanisms
exist for the desensitization of the pathway to maintain
the transience of the IkBa-mediated signaling pathway
reviewed by Ghosh et al., 1998). In cowpox virus-in-
ected cells, there was no apparent change in the quan-
ity of IkBa over the corresponding period after stimula-
tion. Also, TNF treatment of infected cells resulted in the
accumulation of a small portion of IkBa with decreased
electrophoretic mobility. This modified IkBa, which is
etectable on longer exposures of the IkBa immunoblots
Fig. 5B, middle), was specifically detected when the
mmunoblot was repeated with antibody specific for
FIG. 4. Late viral gene expression is not required for cowpox virus to
inhibit nuclear accumulation of NF-kB capable of complex formation
ith kB-site oligonucleotides. Nuclear extracts were prepared both
rom uninfected HEK 293 cells and from cowpox virus-infected HEK 293
ells (5 PFU/cell) at 6 h postinfection. The cells were left untreated
lanes 1 and 5) or were treated with AraC (lanes 2 and 6), TNF (lanes
and 7), or both AraC and TNF (lanes 4 and 8). The nuclear extracts
rom the cells were incubated with radiolabeled oligonucleotides con-
aining a consensus NF-kB binding-site sequence. Resultant complex
ormation was analyzed by EMSA. AraC treatment was at 40 mg/ml for
he entire 6 h; TNF treatment was at 5 ng/ml for 20 min before the cells
ere harvested.
POXVIRUS INTERFERENCE Werine 32-phosphorylated IkBa (Fig. 5B, bottom). This
indicates that IkBa in cowpox virus-infected cells can be
t
cphosphorylated at serine 32 in response to TNF treat-
ment, and that unlike in uninfected cells, this phosphor-
ylated form of IkBa is not rapidly degraded.
Protein synthesis during infection is required for the
inhibition of IkBa degradation by cowpox virus. Infected
HEK 293 cells were treated with cycloheximide for the
duration of the infection, or for an equivalent amount of
time in uninfected cells, and then the effect on TNF-
mediated IkBa degradation was assessed. Cyclohexi-
mide treatment alone did not alter the quantity of IkBa in
the cells (Fig. 6, compare lanes 1 and 5 with 2 and 6) or
prevent the uninfected cells from degrading IkBa after
NF stimulation (Fig. 6, lane 4). However, in the presence
f cycloheximide, cowpox virus did not inhibit IkBa deg-
adation after TNF stimulation as it did in the absence of
ycloheximide (Fig. 6, compare lanes 7 and 8). Taken
ogether with the results from the AraC experiments (Fig.
), these data suggest that early viral protein synthesis,
r virus-induced host protein synthesis, is necessary for
FIG. 5. Cowpox virus inhibits TNF-induced degradation of IkBa.
Cytoplasmic extracts were prepared from uninfected cells (Un.) or cells
that had been infected with cowpox virus (CPV); where indicated, the
cells were treated with 10 ng/ml TNF. Proteins were resolved by
polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocel-
lulose filters for immunoblot analysis. (A) HEK 293 cells (infected with
5 PFU/cell) were treated with TNF for the indicated number of minutes
prior to harvesting the cells at 6 h postinfection. IkBa was detected by
immunoblotting with an antibody against human IkBa. (B) HEK 293T
ells (infected with 10 PFU/cell) were treated with TNF at 4 h post-
nfection for 20 min. Top and middle: two exposures of an immunoblot
ith an antibody against human IkBa. Bottom: the membrane shown in
the top and middle was stripped and phosphorylated IkBa was de-
179HE REGULATION OF NF-kBected with an antibody against a synthetic phospho-Ser32 peptide
orresponding to residues 26–39 of IkBa.
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NF-kB.
Cowpox virus interferes with the process of IkBa
degradation
The inhibition of IkBa degradation by cowpox virus
ould be attributed to interference either with the path-
ay leading to the phosphorylation of IkBa or with sub-
sequent processing of appropriately phosphorylated
IkBa.
Cowpox viruses may encode multiple inhibitors of
omponents of NF-kB activation pathways. For example,
the Brighton Red strain of cowpox virus encodes three
soluble, secreted TNF receptors (CrmB, CrmC, and
CrmD), one of which, the CrmB protein, is an early gene
product (Hu et al., 1994; Smith et al., 1996; Loparev et al.,
998). Thus, one or more of these receptors might con-
ribute to the inhibition of IkBa degradation through in-
erference with the initiation of signaling. However, our
ata indicate that in this system, cowpox virus does not
ompletely block signaling through the cellular TNF re-
eptors, because TNF treatment of infected cells results
n phosphorylation of IkBa on serine 32 (Fig. 5B). More-
over, a cowpox virus variant lacking both copies of the
crmB gene is still capable of inhibiting TNF-mediated
degradation of IkBa (data not shown).
To confirm that cowpox virus affects the process of
signal transduction downstream of the receptor signal-
ing complex, we employed okadaic acid, a protein phos-
phatase inhibitor that elicits IkBa degradation by a
echanism distinct from that of TNF. Okadaic acid (OA)
s thought to induce the phosphorylation and degrada-
FIG. 6. Protein synthesis is required for cowpox virus to inhibit
TNF-mediated IkBa degradation. Cytoplasmic extracts were prepared
from HEK 293 cells either left uninfected or infected with cowpox virus
(5 PFU/cell). Proteins were resolved by PAGE and transferred to nitro-
cellulose filters. IkBa was detected by immunoblotting with antibody
gainst human IkBa and visualized by enhanced chemiluminescence.
As indicated, the cells were left untreated (lanes 1 and 5) or were
treated with cycloheximide (lanes 2 and 6), TNF (lanes 3 and 7), or both
cycloheximide and TNF (lanes 4 and 8). At 4 h postinfection the cells
were harvested and the extracts were analyzed. Cycloheximide treat-
ment was at 100 mg/ml for the entire 4 h; TNF treatment was at 10 ng/ml
for 20 min before the cells were harvested.
180 OIE Aion of IkBa by way of preventing any basally phosphor-
lated, and therefore activated, IkB kinase from beingephosphorylated by cellular phosphatases (Sun et al.,
995; DiDonato et al., 1997). In this way, the okadaic acid
aintains or causes an increased accumulation of active
KK inside the cell even in the absence of activating
timuli such as TNF. When uninfected HEK 293 cells
ere treated with okadaic acid for 1 h, there was a
arked decrease in the quantity of IkBa (Fig. 7, top, lane
). Further, the residual IkBa was distributed between
two forms, a form with the same electrophoretic mobility
as that in unstimulated cells, and a form with a reduced
electrophoretic mobility. After 3 h of okadaic acid treat-
ment, IkBa was not detectable in the uninfected cells. In
cowpox virus-infected cells, okadaic acid treatment did
not induce an equivalent loss of IkBa; after 3 h, much of
the IkBa remained undegraded (Fig. 7, top, lane 8). How-
ver, although the IkBa was not degraded, all of the
protein was converted to species with decreased elec-
trophoretic mobility, consistent with its conversion to
phosphorylated forms. These slower migrating species
were confirmed to be serine 32-phosphorylated IkBa by
tripping the membrane and repeating the immunoblot
ith an antibody specific for IkBa phosphorylated at this
residue, which is one of the two regulatory serines phos-
phorylated by IKK (Fig. 7, bottom). This suggests that the
IkBa was converted to a potential substrate for ubiquiti-
FIG. 7. Cowpox virus inhibits the degradation of phosphorylated
IkBa. Cytoplasmic extracts were prepared from either uninfected HEK
293 cells or cells infected with cowpox virus (5 PFU/ml). At 4 h postin-
fection, the cells were treated with okadaic acid (1 mg/ml) and were
then harvested after the indicated periods of time (lanes 2–4 and 6–8);
cells that were not treated with okadaic acid (lanes 1 and 5) were
harvested at the same time as those treated for 3 h. Proteins were
resolved by PAGE and transferred to nitrocellulose filters. (Top) IkBa
was detected by immunoblotting with antibody against human IkBa.
Bottom) Phosphorylated IkBa was detected with antibody against a
synthetic phospho-Ser32 peptide corresponding to residues 26–39 of
KUPIkBa. The detected proteins were visualized by enhanced chemilumi-
nescence.
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ITH Tnation, because IKK is thought to phosphorylate regula-
tory serines 32 and 36 simultaneously (reviewed by Karin
and Ben-Neriah, 2000). Beyond this, the precise nature
and extent of IkBa phosphorylation in response to oka-
aic acid treatment in cells infected with cowpox virus is
nknown. Nonetheless, this result indicates that cowpox
irus does not inhibit okadaic acid-induced phosphory-
ation of IkBa; rather, it interferes with the subsequent
processing of this phosphorylated IkBa.
The accumulation of phosphorylated IkBa in the oka-
daic acid-treated, virus-infected cells vs the accumula-
tion of predominantly unphosphorylated IkBa in TNF-
treated, virus-infected cells is intriguing (Figs. 5 and 7).
This difference could be attributed either to a partial viral
inhibition of TNF-mediated IkBa phosphorylation or to an
kadaic acid-mediated inhibition of the dephosphoryla-
ion of IkBa. Cowpox virus does possess a homolog of
he VH1 tyrosine/serine phosphatase encoded by vac-
inia virus (Guan et al., 1991; Hakes et al., 1993; unpub-
ished data). However, the phosphatase does not appear
o be required for the viral inhibition of NF-kB signaling
hat we have observed because this inhibition is depen-
ent upon protein synthesis during the early phase of
irus replication, whereas the VH1 gene is expressed
uring the late phase (Rosel et al., 1986). Furthermore,
he VH1 phosphatase is relatively insensitive to okadaic
cid (Guan et al., 1991). Nevertheless, we have not ruled
ut the possibility that the VH1 phosphatase might con-
ribute to additional viral effects upon components of
F-kB signaling pathways, because VH1 phosphatase
packaged in virus particles (Liu et al., 1995) is capable of
dephosphorylating the cellular Stat1 protein, a compo-
nent of the gamma interferon signaling pathway (Najarro
et al., 2001).
Other poxviruses affect the activation of NF-kB in a
ype-specific manner
Cowpox virus was chosen for the initial studies on the
ffects of virus infection on NF-kB activation because
owpox virus possesses one of the largest genomes
mong viruses in the orthopoxvirus genus. Conse-
uently, it was judged to be a good system in which to
egin the search for viral mechanisms capable of affect-
ng the activation of NF-kB.
While most of the viral genes essential for in vitro
growth are conserved between the orthopoxvirus spe-
cies, those conferring accessory functions that affect
virus–host interactions in vivo differ markedly among
species and strains of virus. Therefore, we were inter-
ested in whether the cowpox virus inhibition of the NF-kB
ctivation was a property common among related poxvi-
uses.
To address this question, three different strains of
POXVIRUS INTERFERENCE Waccinia virus (Copenhagen, Western Reserve, and mod-
fied vaccinia Ankara) and one strain of raccoonpox virusV71-I-85A) were examined. Parenthetically, none of
hese strains of vaccinia virus encodes any secreted
NF receptors (Goebel et al., 1990; Howard et al., 1991;
mith et al., 1991; Antoine et al., 1998). Each was inves-
igated for the effects of viral infection on, first, the quan-
ities of nuclear NF-kB capable of binding to kB sites,
and second, IkBa degradation in HEK 293 cells either
with or without TNF treatment. Interestingly, the viruses
acted in a type-specific manner to produce diametrically
different outcomes on the NF-kB activation pathway. In-
ection with vaccinia virus Copenhagen strain, vaccinia
irus Western Reserve strain (data not shown), or rac-
oonpox virus did not induce either the nuclear accumu-
ation of p50/p65 NF-kB capable of binding to kB sites
(Fig. 8A) or the degradation of IkBa (Fig. 8B). Similar to
FIG. 8. Orthopoxviruses affect the activation of the NF-kB pathway in
a type-specific manner. Nuclear and cytoplasmic extracts were pre-
pared from uninfected and poxvirus-infected cells at 4 h postinfection.
Where indicated, the cells were treated with 10 ng/ml of TNF for 20 min
before the cells were harvested. (A) HEK 293 cells were infected with
cowpox virus (CPV), vaccinia virus Copenhagen strain (VV), raccoonpox
virus (Rcn), or modified vaccinia virus Ankara strain (MVA) at 5 PFU/cell.
Nuclear extracts from the cells were incubated with radiolabeled oli-
gonucleotides containing a consensus NF-kB binding-site sequence.
Resultant complex formation was analyzed by EMSA. (B) HEK 293T
cells were infected with CPV, VV, Rcn, or MVA at 10 PFU/cell. Proteins
in the cytoplasmic extracts were resolved by PAGE and transferred to
nitrocellulose filters. IkBa was detected by immunoblotting with an
antibody against human IkBa and visualized by enhanced chemilumi-
nescence.
181HE REGULATION OF NF-kBcowpox virus, each of these three viruses prevented TNF
induction of these events. Additionally, we noted the
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ND PICpresence of minor amounts of apparently virus-specific,
protein–DNA complexes in the nuclear extracts of pox-
virus-infected cells (e.g., Fig. 8A, lanes 3–10). The nature
of these complexes has yet to be determined. In sharp
contrast to these viruses, infection with the modified
vaccinia virus Ankara strain (MVA) induced both the
nuclear accumulation of NF-kB capable of binding to kB
sites (Fig. 8A, lane 9) and the degradation of IkBa (Fig.
B, lane 9), even in the absence of TNF treatment. Of
ote, since MVA is severely host-range restricted com-
ared with other poxviruses, MVA can also induce IkBa
degradation in BHK cells (data not shown), which are
permissive for MVA replication (Carroll and Moss, 1997;
Drexler et al., 1998). This suggests that initiation of IkBa
degradation by MVA is independent of the ability of the
virus to replicate in a cell.
To determine whether MVA infection can result in the
activation of NF-kB-regulated gene expression, we ex-
mined the effects of virus infection upon the expression
f luciferase reporter genes transfected into HEK 293T
ells (Fig. 9). Under the conditions of this assay, MVA
nduced a fivefold reduction in the constitutive expres-
ion of sea pansy luciferase in comparison to uninfected
ells. This is consistent with the more rapid interference
ith host gene expression by MVA in comparison to
owpox virus, most likely as a result of the shorter rep-
ication cycle of MVA. If quantities of the NF-kB-regulated
firefly luciferase were normalized to quantities of sea
pansy luciferase, then MVA induced an apparent fivefold
increase in NF-kB-regulated luciferase gene expression,
which was not increased further by the addition of TNF.
However, to interpret this as evidence that MVA does
induce NF-kB-regulated luciferase gene expression, it is
ecessary to assume that the progressive viral inhibition
f host gene expression affects the reporter gene and
he reference gene equivalently, though it is not certain if
his is the case during an MVA infection. Despite this
aveat, such an interpretation is consistent with the
revious results showing the induction of NF-kB signal-
ing events as a consequence of MVA infection.
In summary, several orthopoxviruses do not activate
NF-kB signaling upon infection and possess the ability to
interfere with signal transduction pathways leading to
NF-kB activation. Other orthopoxviruses, such as MVA,
may activate NF-kB signaling pathways upon infection.
DISCUSSION
This study demonstrates that poxviruses can affect
F-kB-regulated gene expression in the infected host
cell. Further, it shows that poxviruses exert their effects,
either negatively or positively, in a type-specific manner.
Importantly, it shows that poxviruses, by inhibiting the
degradation of IkBa, even after it has been phosphory-
182 OIE Alated, target a point of convergence of multiple signal
pathways leading to the activation of NF-kB.
m
tBy targeting NF-kB-regulated gene expression, the
virus interferes with one of the central regulatory mech-
anisms of the immune system, enabling the virus to
suppress the expression of numerous proteins that con-
tribute to the immune response against infection. Indeed,
many of these host proteins, or the processes in which
these proteins are engaged, are known to be targeted by
poxviruses through other means. These different mech-
anisms of poxviral interference with NF-kB activation
ay well be complementary rather than redundant
FIG. 9. The effect of the modified vaccinia virus Ankara strain on the
expression of a luciferase gene under the control of an NF-kB-regu-
lated promoter. HEK 293T cells were transiently cotransfected with two
vectors: a control vector designed to give constitutive expression of a
sea pansy luciferase gene; and an NF-kB reporter vector for the
inducible expression of a firefly luciferase gene. At 19 h posttransfec-
tion, the cells were either mock-infected with BHK cell lysate or infected
with MVA (10 PFU/cell). Cells were either left untreated or treated with
TNF (20 ng/ml) from 4 to 8 h postinfection and then assayed for both
sea pansy and firefly luciferase activity. (Table) The average of three
independent transfections is represented by each luciferase value. (Bar
graph) The graph shows the relative change in firefly luciferase activity
compared with untreated, mock-infected cells. The firefly luciferase
values are standardized using the sea pansy luciferase values from the
constitutively active promoter.
KUPechanisms. For example, viral soluble, secreted recep-
ors for ligands that can activate NF-kB may contribute to
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ITH Tthe interference with NF-kB-regulated gene expression
n uninfected cells as well as in virus-infected cells. This
pparent multiplicity of mechanisms of inhibition under-
cores the advantage that might be gained by viral sup-
ression of NF-kB-regulated gene expression, presum-
ably because this could delay or impair host immune
responses.
Conversely, viral activation of NF-kB-regulated gene
expression would be expected to stimulate and intensify
immune responses. Viruses of many other families are
known to activate NF-kB, particularly those that take
dvantage of NF-kB-regulated mechanisms of transcrip-
ion of viral genes (reviewed by Hiscott et al., 2001). It is
ess clear whether poxviruses might benefit from the
ctivation of NF-kB. Nevertheless, the finding that MVA, a
virus closely related to other strains of vaccinia virus, is
capable of activating NF-kB by virtue of infection alone is
significant. Although the precise mechanisms involved in
the activation of NF-kB by MVA have yet to be deter-
mined, this finding suggests that orthopoxviruses of
other types may also possess this capacity. The MVA
genome does not contain any genes that do not have
counterparts in the genomes of most other orthopoxvi-
ruses (Antoine et al., 1998). Thus, the viral activation of
NF-kB may reflect the loss of viral function in MVA, rather
than the presence of an MVA-specific inducer of NF-kB.
lternatively, variants of genes that are conserved
mong the orthopoxviruses may confer different capac-
ties to induce NF-kB activation. In this case, it is also
possible that the mechanisms of MVA-mediated activa-
tion of NF-kB might not involve the same signaling path-
ays targeted by cowpox and vaccinia viruses to inhibit
NF-mediated activation of NF-kB. Such an activation
process might pre-empt, or circumvent, or be dominant
over any inhibitory mechanisms that MVA may possess
in common with cowpox virus. In either of these models,
the degree of activation of NF-kB is likely to be depen-
dent upon both the type of virus and the type of cell
infected.
The results of this study may have several implications
for the pathogenesis of poxvirus infections.
First, most of the relatively avirulent poxviruses that we
have examined inhibit NF-kB activation. This suggests
hat in host species natural to the virus, the ability to
nhibit NF-kB may be a contributory factor in the impair-
ent of the immune response to infection. This may
acilitate a productive infection without preventing the
ventual clearance of the virus and recovery of the host.
Second, limited viral activation of NF-kB, which might
occur in the context of a nonproductive infection, such as
MVA infection of humans, may stimulate the immune
response against that infection. However, since MVA
infection appears to be self-limiting, viral activation of
NF-kB might also be somewhat limited. This would be
POXVIRUS INTERFERENCE Wbeneficial from the standpoint of vaccine efficacy. It may
be a major contributory factor to the immunogenicity of
d
aMVA-derived vaccines, which appear to be as effective
as other live vaccinia virus vaccines despite the inability
of MVA to replicate in humans (Sutter et al., 1994; Moss
et al., 1996; Carroll et al., 1997; Belyakov et al., 1998;
Ramı´rez et al., 2000). In effect, the activation of NF-kB
ay act as an adjuvant during these vaccinations.
Third, viral activation of NF-kB in the context of a
productive infection might stimulate the immune re-
sponse, which could lead to an accelerated clearance of
the virus, or alternatively, result in prolonged overexpres-
sion of NF-kB-regulated genes. In the former case, such
response may be protective for the host and limit viral
eplication, perhaps contributing to a limitation on the in
ivo host range of the virus without necessarily restrict-
ng the in vitro host range. An orthopoxvirus that exhibits
host range properties of this type is variola virus. Al-
though variola virus is capable of replicating in cells
derived from a wide variety of nonhuman species, it
lacks the ability to sustain replication in any animal
except humans (reviewed by Fenner et al., 1988a). One
hypothesis to explain this is that variola virus might
induce the limited activation of NF-kB in these nonhu-
man species, resulting in an enhanced immune re-
sponse that curtails viral replication in vivo. However, if
the host were to fail to limit the viral replication, pro-
longed NF-kB activation could lead to the pathology
associated with this host response. The precedence for
this is the endotoxemia that is associated with many
bacterial infections and for which the activation of NF-kB
is a contributory factor (Barnes and Karin, 1997; Bo¨hrer et
al., 1997; Christman et al., 1998; Armstead et al., 1999;
Neish et al., 2000). In this regard it is noteworthy that fatal
effects of variola virus infections of humans have simi-
larities to the effects of bacterial toxemia (Koplan and
Foster, 1979; Fenner et al., 1988b). The molecular mech-
anisms contributing to mortality and morbidity associ-
ated with infections by highly pathogenic orthopoxvi-
ruses such as variola and monkeypox viruses are poorly
understood. For these reasons it may be highly instruc-
tive to determine the properties of some of these or-
thopoxviruses with respect to their effects on NF-kB-
egulated gene expression.
Finally, the results of this study may have several
mplications for the processes contributing to health and
isease in a context broader than that of poxvirus infec-
ions. Several studies have suggested that NF-kB-regu-
ated gene expression may be a major contributory factor
n the pathogenic processes associated with a variety of
nfectious and noninfectious diseases, including rheu-
atoid arthritis, asthma, sepsis, neurodegenerative dis-
rders, and various cancers (reviewed by Chen et al.,
999; Karin and Ben-Neriah, 2000; Baldwin, 2001a,b;
attson and Camandola, 2001). Therefore, a greater un-
183HE REGULATION OF NF-kBerstanding of the mechanisms by which poxviruses
ffect the activation of NF-kB may assist the develop-
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ND PICment of new methods to control the pathogenic effects of
NF-kB activation in a number of these diseases.
MATERIALS AND METHODS
Cell culture
Human embryonic kidney (HEK) 293 and HEK 293T
cells (kindly provided by Dr. K. Burns, University of Lau-
sanne) were maintained in minimal essential medium
(MEM; Gibco BRL, Grand Island, NY) supplemented with
10% fetal bovine serum (FBS; Gibco BRL). Human osteo-
sarcoma 143B cells were maintained in MEM supple-
mented with 5% FBS. Syrian hamster kidney BHK-21
(BHK) cells were maintained in MEM alpha (Gibco BRL)
supplemented with 5% FBS. HeLa cells were maintained
in RPMI 1640 medium (Gibco BRL) supplemented with
5% FBS.
Reagents
Lyophilized recombinant human tumor necrosis factor-
alpha (TNF; R&D Systems Inc., Minneapolis, MN) was
reconstituted at a concentration of 10 mg/ml in a sterile-
filtered solution of phosphate-buffered saline containing
0.1% bovine serum albumin (Sigma, St. Louis, MO); ali-
quots were stored at 280°C. Cycloheximide and AraC
were obtained from Sigma. Okadaic acid (product no. O
9381, Sigma) was resuspended at 25 mg/ml in MEM plus
5% ethanol, according to the manufacturer’s instructions,
and stored at 220°C. Rabbit polyclonal anti-IkBa IgG
C-21), goat polyclonal anti-NF-kB p50 (NLS)-G IgG, and
goat polyclonal anti-NF-kB p65 (C-20)-G IgG were ob-
ained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
A). Normal goat serum was obtained from Vector Lab-
ratories, Inc. (Burlingame, CA). Phospho-IkBa (Ser32)
ntibody was obtained from New England Biolabs Inc.
Beverly, MA).
irus stocks
Cowpox virus (Brighton Red strain), vaccinia virus
Copenhagen and Western Reserve strains), and rac-
oonpox virus (V71-I-85A strain) stocks were grown in
uman 143B cells. The modified Ankara strain of vaccinia
irus (kindly provided by Dr. B. Moss, NIH) was grown in
HK cells as described by Carroll and Moss (1997).
nfection and TNF treatment of cells
Cells were plated the day before infection at approxi-
ately 105 cells/cm2. To achieve an accurate multiplicity
f infection for each experiment, the total number of cells
er dish were determined by hemocytometer counts of
ells in duplicate dishes. Cells were infected at 5 or 10
FU/cell in PBS using a total volume of 300–500 ml for
6-cm dishes or 100 ml for 12-well plates. Cells were
184 OIE Ancubated with the inoculum for 45 min at 37°C. The
noculum was removed and 1.5-ml fresh medium was
t
ldded per 6-cm dish, or 1 ml medium was added per
ell of the 12-well plates. For TNF treatment, an appro-
riate volume of the concentrated stock of TNF was
dded directly to the culture medium.
Nase protection assays
Total cellular RNAs were prepared using the Roche
Indianapolis, IN) High Pure RNA Isolation Kit according
o the manufacturer’s instructions. The hAPO-5 multi-
robe cDNA template set (PharMingen, San Diego, CA)
as used to generate the anti-sense RNA probes for the
Nase protection assays, which were performed using
he PharMingen Riboquant Multi-Probe RNase Protec-
ion Assay System according to the manufacturer’s pro-
ocol. Briefly, RNAs isolated from 5 3 106 cells, in a 2 ml
ol, were mixed with 8 ml radiolabeled probe (3.5 cpm/ml)
n hybridization buffer. The mixture was placed in an
ven prewarmed to 90°C, and then the temperature
etting was immediately changed to 56°C (to allow the
emperature to ramp down slowly) for overnight hybrid-
zation. The next day, any remaining unhybridized probe
r cellular RNA was digested with RNase A, and then the
Nase A was removed by digestion with proteinase K.
ntact RNA was purified by phenol:chloroform extraction
ollowed by ethanol precipitation. The RNA was resus-
ended in 10 ml of 13 loading buffer (PharMingen) and
alf of the sample was resolved by PAGE on a 5%
crylamide gel. The protected probe was detected by
utoradiography of the dried gel.
ransfections and luciferase assays
HEK 293T cells were seeded onto 12-well plates the day
efore being transfected to give 106 cells per well. Cells
ere transfected according to the manufacturer’s protocol
sing 1.5 ml LipofectAMINE 2000 reagent (Gibco BRL) and
0.5 mg DNA, in serum-free MEM, per each well. The DNA
as a 10:1 mix of NF-kB reporter vector to constitutive
xpression vector. The NF-kB reporter vector used was the
Stratagene (La Jolla, CA) pNFkB-Luc plasmid, which gives
nducible NF-kB-dependent expression of firefly (Photinus
pyralis) luciferase driven by a synthetic promoter compris-
ing a TATA box preceded by five direct repeats of the
sequence 59-TGGGGACTTTCCGC-39 containing the NF-kB
inding element first identified in the kappa light chain gene
nhancer (Sen and Baltimore, 1986). The constitutive ex-
ression vector used was the Promega (Madison, WI) pUC-
ased pRL-TK vector, which gives low-level constitutive
xpression of sea pansy (Renilla reniformis) luciferase from
he promoter of the herpes virus thymidine kinase gene. At
5.5 h post-transfection, FBS was added to the medium for
final concentration of 10%. At 19 h post-transfection, the
ulture medium was removed, and the cells were infected
ith 10 PFU/cell, as described above. At 4 h postinfection,
KUPhe cells were treated with 20 ng/ml TNF and harvested 4 h
ater at 8 h postinfection (27 h post-transfection). To harvest
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Dual-Luciferase Reporter Assay System was used accord-
ing to the manufacturer’s instructions, with slight modifica-
tions. Briefly, the cells were scraped into the culture me-
dium and collected by a 10-s centrifugation at 14,000 rpm in
a Sorvall MC 12B centrifuge with an FA-MICRO/1.5 ml rotor.
The supernatant was removed and the cells were centri-
fuged again for about 3 s to allow for the removal of any
residual medium. The cell pellet was lysed in 200 ml of 13
assive lysis buffer (Promega) for 5–10 min at room tem-
erature. The lysates were clarified by 5 min of centrifuga-
ion, and the supernatants were was analyzed for firefly and
ea pansy luciferase activity. For luciferase value determi-
ation, 50 ml of luciferase assay reagent II (Promega)
as mixed with 10 ml of cell lysate and analyzed for fire-
fly luciferase activity with a Turner Design TD-20/20 lumi-
nometer. Then 50 ml of Stop & Glo reagent (Promega)
was added for a determination of sea pansy luciferase
activity.
Preparation of cytoplasmic and nuclear extracts
Extracts were prepared according to a modified ver-
sion of the methods described by Dignam et al. (1983)
nd Lægreid et al. (1994). Briefly, the cells were scraped
nto the culture medium and collected by a 10-s centrif-
gation at 14,000 rpm in a Sorvall MC 12B centrifuge with
n FA-MICRO/1.5 ml rotor. The supernatant was removed
y aspiration and the cell pellet was lysed in approxi-
ately 3 vol of CE buffer [10 mM HEPES, 10 mM KCl, 0.1
M EDTA (pH 8.0), 0.1 mM EGTA, 1 mM DTT, 0.5 mM
MSF, 0.05% NP-40, 2 mg/ml aprotinin, 0.5 mg/ml leupep-
in, 20 mM b-glycerophosphate, 10 mM NaF, and 1 mM
Na3VO4]. After a 5-min incubation on ice, the nuclei were
pelleted with a 20-s centrifugation, and the supernatant
was saved as the cytoplasmic extract. The pelleted nu-
clei were gently washed with 5–10 vol of CE buffer before
being pelleted again with a 20-s centrifugation. Nuclear
extracts were then prepared by resuspending the nuclei
in approximately 3 vol of NE buffer [20 mM HEPES, 25%
glycerol, 0.4 M NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA,
0.5 mM PMSF, 1 mM DTT, 2 mg/ml aprotinin, 0.5 mg/ml
eupeptin, 20 mM b-glycerophosphate, 10 mM NaF, and
1 mM Na3VO4]. The nuclei were incubated in NE buffer
or 10–30 min on ice, and then the debris was pelleted at
4,000 rpm in an Eppendorf 5415 centrifuge for 10 min at
°C. Alternatively, the suspension of nuclei in NE buffer
as sonicated for approximately 1 min on ice to disrupt
he nuclear membranes prior to the centrifugation step.
he supernatant was saved as the nuclear extract and
tored at 280°C.
lectrophoretic mobility shift assays
Electrophoretic mobility shift assays were performed
POXVIRUS INTERFERENCE Wsing a modification of the techniques described by
aldwin et al. (1991) and the manufacturer’s instructionsor the Promega Gel Shift Assay Core System. Briefly, an
ligonucleotide containing an NF-kB binding site con-
sensus sequence (59-AGTTGAGGGGACTTTCCCAGGC-
39) was obtained from Promega and end-labeled with
[g-32P]ATP [Amersham Pharmacia Biotech (Amersham),
iscataway, NJ]. The unincorporated ATP was removed
y passage of the oligonucleotide through a Sephadex
-25 (Amersham) column buffered with TEN [0.1 M NaCl,
0 mM Tris–Cl (pH 8.0), and 1mM EDTA (pH 8.0)]. Nuclear
xtracts, prepared as described above, were incubated
ith the radiolabeled kB-site-containing oligonucleotide
n gel shift buffer [53 buffer is 5 mM MgCl2, 2.5 mM
EDTA (pH 8.0), 2.5 mM DTT, 250 mM NaCl, 50 mM Tris, 25
ng/ml poly(dI-dC) z poly(dI-dC), 20% glycerol] for 20 min at
room temperature. Samples were separated by gel elec-
trophoresis through a 5% acrylamide/TGE [25 mM Tris,
190 mM glycine, 1 mM EDTA (pH 8.0)] nondenaturing gel.
The gel was dried and subjected to autoradiography.
Western blot analysis
Extracts were analyzed using an SDS-PAGE system
(Laemmli, 1970). Cytoplasmic extracts, prepared as de-
scribed above, were mixed with an equal volume of 23
treatment buffer (0.125 M Tris–Cl, 4% SDS, 20% v/v glyc-
erol, 0.2 M DTT, 0.02% bromphenol blue, pH 6.8), boiled
for 5 min, and electrophoretically separated on a poly-
acrylamide gel with a 4% stacking gel and a 12.5%
running gel. The proteins were transferred to a nitrocel-
lulose membrane in transfer buffer [25 mM Tris, 192 mM
glycine, 20% methanol, and 0.1% SDS, pH 8.2 (Towbin et
al., 1979)]. The membrane was blocked with 5% milk in
Tris-buffered saline/0.05% Tween 20 (TBST). Specific pro-
teins were detected with primary antibody diluted 1:5000
in 5% milk/TBST followed by a secondary incubation with
donkey anti-rabbit antiserum conjugated to horseradish
peroxidase (Amersham) diluted 1:5000 in TBST. The
membrane was then incubated in enhanced chemilumi-
nescence substrate (Amersham), and autoradiography
was used to detect the specific proteins.
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